Corrected: Roche’s Tecentriq scores first US approval for subcutaneous PD-L1
Just in time for the first day of ESMO, the FDA has approved its first-ever subcutaneous immunotherapy targeting PD-L1 for cancer.
The new formulation of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
